CA2645982A1 - Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique - Google Patents

Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique Download PDF

Info

Publication number: CA2645982A1
Authority: CA; Canada
Prior art keywords: ave5026; treatment; patients; incidence; bleedings
Prior art date: 2008-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2645982A

Other languages

English (en)

Inventor

Dominique Destree

Paul Chew

Sophie Claudel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis France

Original Assignee

Sanofi Aventis France

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-05

Filing date

2008-12-05

Publication date

2010-06-05

2008-12-05 Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France

2008-12-05 Priority to CA2645982A priority Critical patent/CA2645982A1/fr

2010-06-05 Publication of CA2645982A1 publication Critical patent/CA2645982A1/fr

Status Abandoned legal-status Critical Current

Links

208000032843 Hemorrhage Diseases 0.000 title claims abstract description 55
208000034158 bleeding Diseases 0.000 title claims abstract description 53
231100000319 bleeding Toxicity 0.000 title claims abstract description 52
230000000740 bleeding effect Effects 0.000 title claims abstract description 52
238000011282 treatment Methods 0.000 title claims abstract description 35
239000003146 anticoagulant agent Substances 0.000 title claims abstract description 23
230000002785 anti-thrombosis Effects 0.000 title claims abstract description 20
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 32
238000001356 surgical procedure Methods 0.000 claims description 23
206010014522 Embolism venous Diseases 0.000 claims description 14
208000004043 venous thromboembolism Diseases 0.000 claims description 14
229960000610 enoxaparin Drugs 0.000 claims description 13
238000011321 prophylaxis Methods 0.000 claims description 8
238000013150 knee replacement Methods 0.000 claims description 7
230000009424 thromboembolic effect Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
206010047249 Venous thrombosis Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
206010020100 Hip fracture Diseases 0.000 claims description 3
238000012084 abdominal surgery Methods 0.000 claims description 3
230000008901 benefit Effects 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 2
238000011540 hip replacement Methods 0.000 claims description 2
229920000669 heparin Polymers 0.000 description 22
229960002897 heparin Drugs 0.000 description 16
238000000034 method Methods 0.000 description 14
-1 benzyl ester Chemical class 0.000 description 12
230000000694 effects Effects 0.000 description 11
SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical class C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000003814 drug Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
229940127215 low-molecular weight heparin Drugs 0.000 description 6
230000002980 postoperative effect Effects 0.000 description 6
150000003242 quaternary ammonium salts Chemical class 0.000 description 6
159000000000 sodium salts Chemical class 0.000 description 6
230000009471 action Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229960003872 benzethonium Drugs 0.000 description 4
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 4
229960001950 benzethonium chloride Drugs 0.000 description 4
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 4
229940073608 benzyl chloride Drugs 0.000 description 4
230000032050 esterification Effects 0.000 description 4
238000005886 esterification reaction Methods 0.000 description 4
239000003055 low molecular weight heparin Substances 0.000 description 4
230000007170 pathology Effects 0.000 description 4
238000007127 saponification reaction Methods 0.000 description 4
239000001632 sodium acetate Substances 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
150000008044 alkali metal hydroxides Chemical class 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
206010062237 Renal impairment Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
229940127218 antiplatelet drug Drugs 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000000399 orthopedic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
238000002694 regional anesthesia Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
238000000953 Cochran–Armitage test for trend Methods 0.000 description 1
238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
206010015769 Extradural haematoma Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
208000032562 Spinal haematoma Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000001858 anti-Xa Effects 0.000 description 1
229940127217 antithrombotic drug Drugs 0.000 description 1
239000003698 antivitamin K Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
238000011882 arthroplasty Methods 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
238000012691 depolymerization reaction Methods 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
229960001318 fondaparinux Drugs 0.000 description 1
208000030304 gastrointestinal bleeding Diseases 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000000193 iodinated contrast media Substances 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
238000007477 logistic regression Methods 0.000 description 1
229940118179 lovenox Drugs 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000012829 orthopaedic surgery Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
229940019333 vitamin k antagonists Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2645982A 2008-12-05 2008-12-05 Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique Abandoned CA2645982A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2645982A CA2645982A1 (fr)	2008-12-05	2008-12-05	Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2645982A CA2645982A1 (fr)	2008-12-05	2008-12-05	Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Publications (1)

Publication Number	Publication Date
CA2645982A1 true CA2645982A1 (fr)	2010-06-05

Family

ID=42229321

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2645982A Abandoned CA2645982A1 (fr)	2008-12-05	2008-12-05	Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique

Country Status (1)

Country	Link
CA (1)	CA2645982A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2446891A1 (fr) *	2010-10-28	2012-05-02	Aventis Pharma S.A.	Semuloparin pour utilisation comme traitement antithrombotique en chirurgie abdominale majeure avec une sécurité améliorée en termes de saignements cliniquement pertinents et saignements majeurs
WO2012055843A1 (fr) *	2010-10-28	2012-05-03	Aventis Pharma S.A.	Sémuloparine pour la prévention d'une trombo-embolie veineuse majeure chez un patient subissant une chirurgie abdominale majeure
US20130101524A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
US20130102565A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopedic surgery
US20130102566A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings

2008
- 2008-12-05 CA CA2645982A patent/CA2645982A1/fr not_active Abandoned

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130101524A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
US20130102565A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopedic surgery
US20130102566A1 (en) *	2010-06-25	2013-04-25	Aventis Pharma S.A.	Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP2446891A1 (fr) *	2010-10-28	2012-05-02	Aventis Pharma S.A.	Semuloparin pour utilisation comme traitement antithrombotique en chirurgie abdominale majeure avec une sécurité améliorée en termes de saignements cliniquement pertinents et saignements majeurs
WO2012055843A1 (fr) *	2010-10-28	2012-05-03	Aventis Pharma S.A.	Sémuloparine pour la prévention d'une trombo-embolie veineuse majeure chez un patient subissant une chirurgie abdominale majeure
WO2012055844A1 (fr) *	2010-10-28	2012-05-03	Aventis Pharma S.A.	Sémluparine destinée à être utilisée en tant que traitement antithrombotique dans une chirurgie abdominale majeure ayant une sécurité améliorée en termes de saignements cliniquement pertinents et de saignements majeurs

Publication	Publication Date	Title
Eriksson et al.	2003	The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
Rajgopal et al.	2008	The effects of heparin and low molecular weight heparins on bone
Ciccone et al.	2014	Bemiparin, an effective and safe low molecular weight heparin: a review
Cosmi et al.	2012	Old and new heparins
CN102114031A (zh)	2011-07-06	使用于炎症性肠疾病治疗和预防的透明质酸混合物
CA2645982A1 (fr)	2010-06-05	Utilisation de l'ave5026 pour reduire la frequence des saignements durant un traitement antithrombotique
JP5636225B2 (ja)	2014-12-03	炎症性腸疾患（ｉｂｄ）の治療及び予防に使用するための医薬組成物
US20210308228A1 (en)	2021-10-07	Method for reducing the occurrence of thrombosis or thromboembolism
US20120322760A1 (en)	2012-12-20	Methods of treatment with a low molecular weight heparin composition
Pineo et al.	2004	Oral delivery of heparin: SNAC and related formulations
US6258798B1 (en)	2001-07-10	Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
Mousa	2002	The low molecular weight heparin, tinzaparin, in thrombosis and beyond
Turpie	2001	Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice
AU2008255191A1 (en)	2010-06-24	Use of Ave5026 for minimizing the incidence of bleedings during an antithrombotic treatment
JPH10218902A (ja)	1998-08-18	低分子化硫酸化多糖、その製造法及び医薬組成物
Hoy et al.	2010	Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis
Del Bono et al.	2011	Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
Kishimoto et al.	2009	M118–A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes
CA2458852A1 (fr)	2003-03-06	Compositions antithrombotiques comportant de l'heparine de faible poids molecule et du dermatane sulfate de poids moleculaire
US20060286088A1 (en)	2006-12-21	Administration of enoxaparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction
Turpie	2001	Setting a standard for venous thromboembolism prophylaxis
BRPI0806039A2 (pt)	2010-09-14	uso de ave5026 para minimizar a incidência de sangramentos durante um tratamento antitrombótico
Pineo et al.	2004	Dalteparin: Pharmacological Properties AND Clinical
Jones et al.	2003	Is there a role for pentosan polysulfate in the prevention of calcium oxalate stones?
Bates et al.	1998	The new heparins

Legal Events

Date	Code	Title	Description
2014-01-30	FZDE	Dead	Effective date: 20131205